share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/06/21 13:33

Moomoo AI 已提取核心訊息

Allarity Therapeutics received a notice from Nasdaq Listing Qualifications Staff on June 18, 2024, citing non-compliance with the minimum bid price requirement. The company failed to maintain a closing bid price above $1 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).The company plans to request a hearing before the Nasdaq Hearings Panel to maintain its listing status while working towards compliance. This hearing request will temporarily stay the suspension of trading and delisting of the company's common stock. Trading will continue on the Nasdaq Capital Market at least until the Panel makes its decision.However, there is no guarantee that the Panel will grant Allarity's request for continued listing or suspension of delisting. The company must demonstrate its ability to meet Nasdaq's listing requirements to maintain its position on the exchange.
Allarity Therapeutics received a notice from Nasdaq Listing Qualifications Staff on June 18, 2024, citing non-compliance with the minimum bid price requirement. The company failed to maintain a closing bid price above $1 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).The company plans to request a hearing before the Nasdaq Hearings Panel to maintain its listing status while working towards compliance. This hearing request will temporarily stay the suspension of trading and delisting of the company's common stock. Trading will continue on the Nasdaq Capital Market at least until the Panel makes its decision.However, there is no guarantee that the Panel will grant Allarity's request for continued listing or suspension of delisting. The company must demonstrate its ability to meet Nasdaq's listing requirements to maintain its position on the exchange.
2024年6月18日,Allarity Therapeutics公司收到納斯達克上市資格工作人員的通知,由於其普通股買盤價格連續30個工作日低於每股1美元的最低要求,公司不符合納斯達克上市規則5550(a)(2)。公司計劃請求納斯達克聽證委員會的聽證會,以尋求繼續上市,同時努力恢復符合要求。提出聽證請求會推遲交易暫停和可能的股票退市,直到委員會做出決定。Allarity Therapeutics公司警告稱,沒有保證委員會會允許公司繼續在納斯達克資本市場上市。
2024年6月18日,Allarity Therapeutics公司收到納斯達克上市資格工作人員的通知,由於其普通股買盤價格連續30個工作日低於每股1美元的最低要求,公司不符合納斯達克上市規則5550(a)(2)。公司計劃請求納斯達克聽證委員會的聽證會,以尋求繼續上市,同時努力恢復符合要求。提出聽證請求會推遲交易暫停和可能的股票退市,直到委員會做出決定。Allarity Therapeutics公司警告稱,沒有保證委員會會允許公司繼續在納斯達克資本市場上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息